Streetbeat News

Price Targets

NPO

KeyBanc Capital Markets analyst Jeffrey D. Hammond has reiterated an Overweight rating on EnPro Industries Inc (NYSE:NPO), raising the price target to $158 from $145. Hammond is optimistic about the company's core businesses within the Sealing Technologies segment. He expects 2Q revenues of $171.4 million in this segment. Hammond also notes that EnPro is beginning to see synergies between Leanteq and NxEdge, and considers the company a key beneficiary of CHIPS Act investment. He believes NPO shares are undervalued at current levels and expects valuation multiples to re-rate higher in the long term.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 6:50 pm

BTCY

H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on Biotricity, Inc. (NASDAQ:BTCY), raising the price target to $4 from $2. The analyst acknowledged Biotricity's sales and targeted margin growth, AI tech infusion, and the opportunity to bring its platform solution to associated cardiac-related diseases. For FY24, the analyst's sales estimate stands at $13.8 million, representing an expected 44% annual growth. However, an investment in Biotricity is subject to risks like dilution, end-market product acceptance and pricing, and competition.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 6:41 pm

FIS

A significant amount of unusual options activity has been observed for Fidelity National Info (NYSE:FIS), with a mix of bullish and bearish stances. The trades range from $57.5 to $70.0. The price of FIS is currently up 3.62% at $60.1. Baird maintains an Outperform rating with a price target of $75, while Susquehanna downgraded its action to Positive with a price target of $81.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 6:31 pm

CP

Credit Suisse analyst Ariel Rosa has reiterated a Neutral rating on Canadian Pacific Kansas City Ltd (CPKC) and raised the price target from $81 to $87. CPKC expects to achieve mid-single-digit EPS growth in 2023 and double-digit annual EPS growth over 2024-28. However, the analyst warns that CPKC's high valuation premium and the need for significant operating margin improvement over the next 3 years call for caution.

Portfolio Pulse from Shivani Kumaresan

July 05, 2023 | 6:16 pm

MSFT

In the last quarter, 49 analysts have provided ratings for Microsoft (NASDAQ:MSFT), with a majority being bullish. The company has an average 12-month price target of $341.59, up by 9.24% from the previous average price target of $312.71.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 6:00 pm

DHI

Analysts have provided various ratings for D.R. Horton (NYSE:DHI) in the last quarter, with a total of 5 bullish, 3 somewhat bullish, 3 indifferent, and 1 somewhat bearish. The company has an average 12-month price target of $125.17, which is a 13.7% increase from the previous average price target of $110.09.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 6:00 pm

SPXC

UBS has downgraded SPX Technologies from Buy to Neutral, but increased its price target from $80 to $90. This has led to a decrease in the trading price of SPX Technologies shares.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 5:43 pm

TW

Tradeweb Market shares are trading lower after Piper Sandler maintained a Neutral rating on the stock and lowered its price target from $82 to $70.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 5:20 pm

TTI

EF Hutton analyst Tim Moore has reiterated a 'Buy' rating on Tetra Technologies (NYSE:TTI) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 4:47 pm

FDMT

Chardan Research analyst Geulah Livshits initiated coverage on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with a Buy rating and a price target of $30. The analyst is optimistic about the company's directed evolution of the Adeno-associated virus platform, or AAV, to tackle historical obstacles in vivo gene delivery. The company's pipeline, which includes three clinical-stage ophthalmology assets, is also praised. The analyst believes that discussions with the FDA on pivotal endpoints in 4Q should provide visibility on the path to market.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 4:45 pm